Antiplatelet Therapy and Cardiovascular Diseases
Most cited papers
- Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-AnalysisCerebrovascular Diseases · 2014 · 11,609 citations
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine · 2009 · 7,173 citations
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ · 2002 · 6,953 citations
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine · 2007 · 6,831 citations
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine · 2001 · 6,471 citations
- Clinical End Points in Coronary Stent TrialsCirculation · 2007 · 5,502 citations
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine · 1997 · 5,493 citations
- Optimal Medical Therapy with or without PCI for Stable Coronary DiseaseNew England Journal of Medicine · 2007 · 4,739 citations
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation · 2011 · 4,572 citations
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine · 2003 · 4,216 citations
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ · 1994 · 4,215 citations
- Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaNew England Journal of Medicine · 2018 · 3,463 citations
Metadata from OpenAlex (CC0).